Systemic inflammation is a determinant of outcomes of CD40 agonist–based therapy in pancreatic cancer patients
Agonistic anti-CD40 monoclonal antibody (mAb) therapy in combination with chemotherapy (chemoimmunotherapy) shows promise for the treatment of pancreatic ductal adenocarcinoma (PDA). To gain insight into immunological mechanisms of response and resistance to chemoimmunotherapy, we analyzed blood sam...
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Makale |
| Dil: | English |
| Baskı/Yayın Bilgisi: |
American Society for Clinical investigation
2021-03-01
|
| Seri Bilgileri: | JCI Insight |
| Konular: | |
| Online Erişim: | https://doi.org/10.1172/jci.insight.145389 |